TARA Biosystems is a technology company.
TARA Biosystems has raised $10.0M across 1 funding round.
TARA Biosystems has raised $10.0M in total across 1 funding round.
TARA Biosystems was a biotechnology company that developed highly physiological, human-relevant "heart-on-a-chip" tissue models using induced pluripotent stem cells (iPSCs) to predict drug efficacy and cardiotoxicity.[2][1][5] Its flagship Biowire™ II platform created 3D cardiac tissues mimicking human heart functions, serving pharmaceutical companies by providing early preclinical data to reduce drug development costs and failure rates—addressing the issue where nearly 90% of drugs fail cardiotoxicity tests.[1][2] The company solved a critical problem in drug discovery: expensive late-stage failures due to poor heart safety predictions, enabling faster, more accurate testing for better patient outcomes.[1][6][7] TARA achieved significant growth through partnerships (e.g., with Scipher Medicine) and a Series A round before its acquisition by Valo Health in January 2022, integrating its tech into Valo's AI-powered drug discovery platform focused on cardiovascular diseases.[2][3][4][8]
TARA Biosystems emerged in 2013 from Columbia University's labs, sparked by a conversation between Misti Ushio (from VC firm Harris & Harris, ex-Columbia Technology Ventures) and researchers exploring commercialization of tissue engineering for in vitro drug testing.[1] Key founders included Milica Radisic (Professor at University of Toronto), Kacey Ronaldson (Ph.D. '11SEAS, '15GSAS), Boyang Zhao, and Yimu Zhao (both Ph.D. students at Toronto)—a team of four women biomedical engineering postdocs, three under 30, guided by Columbia Professor Gordana Vunjak-Novakovic.[1] The idea built on Gordana's cardiac platform, proven successful in her lab, targeting pharma's high cardiotoxicity testing costs; early support came from NIH, FDA, and NCATS.[1] Headquartered in New York City's Alexandria Center for Life Science, TARA gained traction via its proprietary models and collaborations, culminating in its 2022 acquisition by Valo Health.[1][2][3]
TARA stood out in biotech through these key strengths:
TARA rode the wave of organ-on-a-chip and AI-drug discovery trends, providing human-relevant models amid rising demand for alternatives to animal testing and 2D cell cultures, accelerated by FDA/NCATS tissue-chip initiatives.[1][2] Timing was ideal: post-2010s stem cell advances (iPSCs) met pharma's need to slash $2B+ drug failure costs, especially in cardio (a top attrition cause).[1][2] Market forces like AI integration (via Valo) and global partnerships favored TARA, influencing the ecosystem by boosting predictive toxicology, enabling precision medicine, and reducing clinical trial attrition—paving the way for faster therapies in cardiovascular diseases.[2][4][7][8]
Post-2022 acquisition, TARA's platform powers Valo Health's vertically integrated cardiovascular efforts, likely expanding into AI-optimized drug pipelines with global reach.[2][8] Trends like multi-organ chips, advanced iPSCs, and regulatory pushes for human data will amplify its impact, potentially evolving Valo's influence toward personalized cardio treatments and broader therapeutic acceleration.[2][4][7] As a pioneer in biofidelic tissues, TARA's legacy underscores how engineered human models transform drug discovery from costly guesswork to predictive precision, delivering better health faster.[1][6]
TARA Biosystems has raised $10.0M in total across 1 funding round.
TARA Biosystems's investors include OMX Ventures.
TARA Biosystems has raised $10.0M across 1 funding round. Most recently, it raised $10.0M Series A in June 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2020 | $10.0M Series A | OMX Ventures |